Alesi Surgical appoints Todd Usen to its Board of Directors to help spearhead global expansion

Alesi Surgical appoints Todd Usen to its Board of Directors to help spearhead global expansion.

Cardiff, U.K. (June 6th, 2022). Alesi Surgical Limited, a leading innovator of minimally invasive surgery technologies – including the world-first Ultravision device – is delighted to announce the appointment of Mr. Todd Usen to its board of directors, with immediate effect. Based in Boston, Massachusetts, Mr. Usen has been appointed a non-executive director of the Company. Todd is currently CEO of Activ Surgical, a pioneering digital intelligence company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Founded in 2017, Activ Surgical is a first-of-its-kind digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility for both endoscopic and robotically assisted procedures. Prior to establishing Activ Surgical, Mr. Usen held senior leadership positions in global medical devices companies including Boston Scientific, Smith and Nephew, and Olympus Corporation of the Americas, where he was President of the Medical Systems Group.

Todd is an executive leader who is skilled in building, restructuring, and growing commercial and operational organizations in both top and bottom line. Responsible for developing and directing the short- and long-term strategic vision, product development, logistics, distribution, go-to-market strategy, and M&A activities. He has managed multi-billion-dollar P&Ls as well as had success raising multiple Venture Capitalist led fundraising rounds in his current role. His experience will greatly facilitate the delivery of Alesi’s vision of disrupting the $2.4bn electrosurgical instrument market, through the integration of its proprietary bioaerosol-control platform, Ultravision, with electrosurgical instruments used in minimally invasive, robotic, and open surgery.??

Todd Usen commented: “I have witnessed the existing Ultravision product in action, spoken to product users, and seen Alesi’s exciting R&D pipeline. Through its unique mode of action, Ultravision clearly helps surgeons, nurses, patients, and healthcare providers deliver best-in-class care. This is an incredibly exciting time for the business, and I look forward to supporting Dominic and the Alesi team in the delivery of its objectives.”

Dominic Griffiths, CEO of Alesi Surgical, commented: “I have been aware of Todd and the incredible work that he is doing with the team at Activ Surgical for some time. With his wealth of experience and broad connections across the industry, we consider ourselves fortunate to have attracted someone of his calibre to our business. The entire Alesi team is excited to start working with him, as we look to shape the future of electrosurgery”.

Notes to editors:

For more information, please contact Alesi Surgical on +44 (0) 29 2029 1022.

1. Alesi Surgical?develops and commercialises products that improve the safety, efficiency, and outcomes of advanced surgical procedures. The company was founded as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), with the vision of becoming a world leader in surgical devices.?Part of Cardiff University, WIMAT runs multi-disciplinary training courses across a range of surgical and medical specialties and is the busiest multi-disciplinary training centre in the United Kingdom. Alesi Surgical is based at?Cardiff Medicentre, the dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus. The latter is also home to Cardiff University’s?School of Medicine.?For more information, visit?alesi-surgical.com.
2. About IP Group. IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, visit?ipgroupplc.com?.
3. About Panakes Partners. Panakès?Partners is a Venture Capital investor that finances medical companies, early stage startups and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields.?Panakès?Partners is headquartered in Milan, Italy. For more information, visit?panakes.it.
4. Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company and supports its portfolio companies with financial resources, strategic support, as well as access to an international network and capital markets. Earlybird invests out of a family of focused and independently managed funds: Digital West (Western Europe), Digital East (Emerging Europe), Healthcare, UNI-X (University spinoffs), and Growth Opportunity. With EUR 2 billion under management, 8 IPOs, and 30 trade sales, Earlybird is one of Europe’s most established and active venture capital firms. For further information: www.earlybird.com, Twitter: https://www.twitter.com/EarlybirdVC. LinkedIn: www.dhirubhai.net/company/earlybird-venture-capital or Facebook: www.facebook.com/EarlybirdVC
5. About Norgine Ventures. Norgine Ventures is backed by Norgine, a private, European healthcare company with 115?years of experience in the pharma space. Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. To date, Norgine Ventures has invested in over twenty businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle. For further information:?https://www.norgineventures.com/